ORIC Pharmaceuticals announced that its management will participate in three investor conferences in November 2026: Guggenheim’s Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference. The company will engage in fireside chats and one-on-one meetings, with webcasts available on its website. ORIC focuses on developing cancer treatments targeting therapeutic resistance, with key products in clinical stages for prostate cancer and non-small cell lung cancer. These events provide ORIC an opportunity to update investors on its progress and future plans.
ORIC Pharmaceuticals is set to participate in multiple investor conferences in November 2026. For readers following the Health sector, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: Of 150 priced Health-sector US stocks tradable on Pluang, 92 rose and 55 fell today. Notable movers include NBIX at USD 165.00 with a 1-day change of +13.52% and Pluang order activity showing 91% Sell / 9% Buy, INO at USD 1.65 down -12.96% with 53% Sell / 47% Buy, and IOVA at USD 8.86 up +10.47% with 99% Sell / 1% Buy. Typical hold times on Pluang range from 4 to 41 days among these stocks.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
Atlanticus Holdings Corporation announced that its CEO Jeff Howard and CFO Bill McCamey will participate in the KBW Fintech Ecosystem Conference in New York from November 10-12, 2026. Jeff Howard will join a fireside chat titled “Beyond the Credit Sc...
United Fire Group reported a 10% decline in Q3 2026 net income to $35.1 million, or $1.34 per diluted share, despite a 13% increase in net written premiums driven by commercial business growth. The combined ratio rose to 94.6% from 91.9% due to highe...
Curaleaf Holdings reported third quarter 2026 net revenue of $353 million, up 11% year-over-year, driven by 8% domestic and 28% international growth. The company achieved an adjusted gross profit margin of 49% and adjusted EBITDA of $78 million, refl...
